obesity
-
Merck secures landmark FDA approval for cholesterol pill Lipfendra
The approval marks the first oral PCSK9 inhibitor, offering patients an alternative to injectable therapies traditionally used to reduce LDL cholesterol levels.
-
Dr. Reddy’s halts generic semaglutide supply due to API quality issues
The setback comes at a crucial time as competition intensifies in the fast-growing market for lower-cost versions of Novo Nordisk’s blockbuster diabetes and obesity medicine.
-
Novo Nordisk collaborates with Vivani Medical to evaluate semaglutide implant for chronic weight management
Under the agreement, Novo Nordisk will internally assess Vivani’s investigational NPM-139 implant, which utilizes the company’s proprietary NanoPortal technology to deliver semaglutide continuously over extended periods through a miniature subdermal device.
-
Mayo Clinic discovers hormone replacement improves tirzepatide obesity treatment
Researchers found that postmenopausal women taking hormone therapy while receiving tirzepatide lost approximately 35% more weight than women treated with tirzepatide alone.
-
Eli Lilly signs US$1.26B deal with Hanmi for long-acting GLP-2 intestinal therapy
Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.
-
Novo Nordisk launches Wegovy oral weight-loss pill in UAE as first international market
Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management.
-
NYU collaborates with Cleveland Clinic Abu Dhabi to develop ‘Lily’ Stent to treat bariatric surgery leaks
The innovation aims to enhance fluid drainage, speed up recovery, and potentially reduce the need for additional corrective procedures.
-
EMA panel recommends approval for Novo Nordisk’s new Wegovy 7.2 mg single-dose pen
Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.
-
Novo Nordisk to present new Semaglutide MASH data from ESSENCE trial at EASL 2026
The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.
-
GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market
The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.